



Oroma Nwanodi
Locum Tenens, USA

Nutraceuticals: Nongynecologic Cancer Chemoradiation Sensitizers, Chemopreventives and Adverse Effect Resolvers

Nutraceutical chemoradiation sensitization can reduce conventional chemoradiation dosing, in turn reducing conventional chemoradiation adverse effects, while maintaining chemoradiation therapeutic effectiveness. Nutraceuticals also prevent and treat chemoradiation adverse effects from anxiety and depression through xerostomia. Improved quality of life motivates up to 75% of integrative oncology users. Nutraceutical chemoprevention should motivate everyone towards healthy diet consumption. Diindolymethane and indole-3-carbinol can sensitize pancreatic cancer to conventional chemotherapy. Sulforaphane chemosensitizes arsenic trioxide, doxorubicin, and gemcitabine. Turmeric is synergistic with docetaxel in lung cancer treatment. Inositol hexakisphosphate chemosensitizes for irinotecan colon cancer therapy. Withaferin A is synergistic with doxorubicin. Curcumin radiosensitizes prostate cancer, polyunsaturated fatty acids radiosensitize renal cancers, and sulforaphane radiosensitizes head and neck cancers. Some Ferula species derived monoterpenes independently reverse multidrug resistance via p-glycoprotein inhibition.

Other Ferula species derived monoterpenes need synergism with vinblastine to reverse multidrug resistance. Fermented nutraceuticals may offer additional micro-organism derived chemopreventive properties. Diets can now be targeted against a given type of cancer. Individual nutraceuticals such as rice bran possess multiple encompassing chemopreventive mechanisms of action: anti-oxidation, anti-proliferation/pro-apoptosis, immune modulation, and mucosal protection. Chemoradiation sensitization equivalence, anti-angiogenesis, and immune modulation are a few areas for future research. Chemopreventive dietary research can explore the quality of consumed products in addition to component portions. Nutraceutical chemoradiation sensitization has the potential to positively affect most cancer patients.

Biography

Oroma Nwanodi graduated from Meharry Medical College of Nashville, Tennessee in USA as a Medical Doctor in 2001. She specialized in Obstetrics and Gynecology at The University of Massachusetts and Maimonides Medical Center. In 2013 and 2014, she obtained specialization in Integrative Holistic Medicine. In 2016, she completed the Doctor of Health Science program at A T Still University, Mesa, Arizona. She has practiced in California, Missouri, Minnesota, and Wyoming. She has published more than 25 papers in reputed journals and serves as an Editorial Board Member for several journals.

o.nwanodi@juno.com